deltatrials

Psoriatic arthritis Trials in Białystok, Poland

Conditions / Psoriatic arthritis / Białystok, Poland

Clinical trials for Psoriatic arthritis investigate a range of treatment strategies and patient populations.

29 total trials for this combination

Showing top 10 of 29 trials

Trials

NCT ID Title Status Phase
NCT03895203 A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis COMPLETED PHASE3
NCT01307423 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) COMPLETED PHASE3
NCT03410992 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis COMPLETED
NCT03370133 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis COMPLETED
NCT03410992 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis COMPLETED
NCT04908202 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs ACTIVE_NOT_RECRUITING
NCT03370133 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis COMPLETED
NCT06671483 A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines RECRUITING PHASE3
NCT03410992 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis COMPLETED
NCT03675308 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy ACTIVE_NOT_RECRUITING PHASE3

Related Pages